TY - JOUR
T1 - Serum cystatin C level is associated with locomotive syndrome risk and can be an early predictor in community-living people
T2 - The Yakumo study
AU - Tanaka, Satoshi
AU - Ando, Kei
AU - Kobayashi, Kazuyoshi
AU - Hida, Tetsuro
AU - Ito, Kenyu
AU - Tsushima, Mikito
AU - Morozumi, Masayoshi
AU - Machino, Masaaki
AU - Ota, Kyotaro
AU - Seki, Taisuke
AU - Suzuki, Koji
AU - Nishida, Yoshihiro
AU - Ishiguro, Naoki
AU - Hasegawa, Yukiharu
AU - Imagama, Shiro
N1 - Publisher Copyright:
© 2018, © 2018 Japan College of Rheumatology.
PY - 2018/11/2
Y1 - 2018/11/2
N2 - Objectives: The locomotive syndrome (LS) risk has been recently proposed as a criterion for evaluating physical ability. Serum cystatin C level is an early renal function marker and a cardiovascular disease predictor. This study aimed to evaluate the relationship between serum cystatin C level and LS risk. Methods: We enrolled 54 participants and conducted the two-step test, stand-up test, 25-question geriatric locomotive function scale, LS risk test, Timed Up and Go test, back muscle strength, grip strength, blood test and serum cystatin C level measurement. A comparative study was conducted in participants with and without LS risk and in subgroups aged <60 and ≥60 years. Results: No significant difference was found in the serum cystatin C level in subgroups aged <60 years and without LS risk. However, it was significantly higher in subjects with LS risk and aged ≥60 years. The area under the curve of the serum cystatin C level for LS risk was 0.824. Conclusion: The serum cystatin C level is significantly related to LS risk and can be an early predictor. In middle-aged and elderly people with high serum cystatin C levels, it is strongly recommended to enforce LS risk test and intervention.
AB - Objectives: The locomotive syndrome (LS) risk has been recently proposed as a criterion for evaluating physical ability. Serum cystatin C level is an early renal function marker and a cardiovascular disease predictor. This study aimed to evaluate the relationship between serum cystatin C level and LS risk. Methods: We enrolled 54 participants and conducted the two-step test, stand-up test, 25-question geriatric locomotive function scale, LS risk test, Timed Up and Go test, back muscle strength, grip strength, blood test and serum cystatin C level measurement. A comparative study was conducted in participants with and without LS risk and in subgroups aged <60 and ≥60 years. Results: No significant difference was found in the serum cystatin C level in subgroups aged <60 years and without LS risk. However, it was significantly higher in subjects with LS risk and aged ≥60 years. The area under the curve of the serum cystatin C level for LS risk was 0.824. Conclusion: The serum cystatin C level is significantly related to LS risk and can be an early predictor. In middle-aged and elderly people with high serum cystatin C levels, it is strongly recommended to enforce LS risk test and intervention.
UR - http://www.scopus.com/inward/record.url?scp=85042945271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042945271&partnerID=8YFLogxK
U2 - 10.1080/14397595.2018.1441675
DO - 10.1080/14397595.2018.1441675
M3 - Article
C2 - 29442538
AN - SCOPUS:85042945271
SN - 1439-7595
VL - 28
SP - 1035
EP - 1040
JO - Modern Rheumatology
JF - Modern Rheumatology
IS - 6
ER -